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Abstract 
Tumor escape is one major obstacle that has to be addressed prior to designing and 
delivering successful immunotherapy. There is compelling evidence to support the 
notion that immunogenic tumors, in murine models and cancer patients, can be 
rejected by the immune system under optimum conditions for activating adaptive and 
non-adaptive anti-tumor immune responses. Despite this capability, a large number of 
tumors continue to grow and evade recognition and/or destruction by the immune 
system. The limited success in current immunotherapeutic strategies may be due to a 
variety of reasons: failure of effector cells to compete with the growing tumor burden, 
production of humoral factors by tumors that locally block cytotoxicity, antigen / 
MHC loss, T-cell dysfunction, production of suppressor T – cells to name but a few or 
therapy ineffectiveness for the particular malignancy being treated. To optimise 
immunotherapy strategies correction of immune activating signals, eradication of 
inhibitory factors and the evasion from newly developed immunoresistant tumor 
phenotypes need to be simultaneously considered.   
 
Introduction 
The immune defence mechanisms are the least effective and the final barrier in the 
natural mechanisms against cancer formation (carcinogenesis) (49). Both innate and 
adaptive immunity induce anti-tumor effects via the activity of NK cells, NKT cells, 
macrophages, neutrophils, eosinophils, various cytokines and specific CTLs to name 
but a few. However spontaneous regression is rarely observed in malignant tumors, 
hence the need for immunotherapeutic intervention is required in order to eradicate 
the tumor. 
 Advances in both molecular and cellular immunology have improved our 
understanding of tumor-host interactions, although much still remains elusive despite 
the progress made in identifying a large number of tumor antigens and new 
immunotherapeutic strategies. The majority of tumors manage to “escape recognition” 
and currently there are a number of mechanisms known for tumor escape which have 
been described – loss / downregulation of HLA Class I, downregulation, mutation or 
loss of tumor antigens, alterations in cell death receptor signalling, production of 
immunosuppressive cytokines and suppressor T-cells and the involvement of
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indoleamine 2,3-dioxygenase in suppression - all of which will be discussed in detail 
later. 
It is believed that a T-cell response does exist but is ineffective as the effector phase 
of the immune response is inadequate. This notion may explain why current 
immunotherapeutic strategies have limited success. From the immunological 
perspective efficient therapeutic intervention should focus on boosting existing anti-
tumor responses and to sustain large numbers of effector T cells at the tumor site.  
Recently, this was clearly demonstrated in melanoma patient where T cell responses 
to vaccines occurred primarily in the presence of pre-activated T cells prior to 
vaccination (111). Analyses of cell mediated immunity against defined melanoma 
antigens using tetramer staining and an IFN- secretion assay suggested that specific 
T cell responses often exist during tumor progression (99). Adjuvants such as 
cytokines have been used when immunising with peptides and proteins 
(48,54,100,118). Immunisation with DNA vaccines leads to the expression of tumor 
antigens and their processing by antigen presenting cells (APCs) (112), whereas the 
direct delivery of antigens as proteins by cell fusion or cDNA to dendritic cells (DCs) 
represents a more direct attempt to generate antitumor responses (2).  
Some anti-tumor therapeutic interventions have met with limited success which has 
been attributed mainly to the “tumor – escape” phenomena i.e. tumor cells have the 
ability to evade immune recognition and/or destruction, causing major obstacles in 
using this modality for the treatment of cancer. This was clearly demonstrated in 
prostate tumor (TRAMP-C1) model where the injection of Fms-like tyrosine kinase-3 
ligand (flt3-L) induced short-term tumor stabilization and regression followed by tumor 
relapse (21). Failure of therapy in this model revealed several important 
immunosuppressive characteristics of the prostate tumor microenvironment including 
the down regulation of MHC class II in DCs, profound deficiency in the expression of 
CD3ε  (CD3epsilon) and the beta chain of the T cell receptor (TCR) of tumor-
associated T cells. Cancer cells can be detected and destroyed by cytotoxic T 
lymphocytes (CTLs) in many experimental models and human tumors but on diagnosis 
the metastasis of many human tumors can be shown to correlate with unresponsive T 
cells. Progressive tumor growth occurs, in part, because the cancer cell is capable of 
escaping immune recognition and not because the immune system is defective (16). 
CML patients for example possess CTLs detectable by tetramer staining and 
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cytotoxicity that recognise HLA-A3 restricted peptide, although the number of CTLs 
may be too few to mediate complete rejection of the cancer (23). 
 Deletion or suppression of activated CTLs can occur as well as their migration away 
from the tumor site. The precursor frequency can be too low, such that the effector cells 
fail to compete with the growing tumor burden. However, it is equally possible that the 
therapies are ineffective for the particular malignancy being treated. In order to fully 
appreciate the role of tumor escape in the failure of immunotherapy, an understanding 
of the basic principles of immunosurveillance and its role in determining tumor 
phenotypes is necessary. 
The hypothesis first proposed by Thomas & Burnet in the 1970s implied that the 
immune response to tumor occurred at an early stage in tumor development – 
“eradicating the cancer before it became apparent” (28,87). 
Many studies have evolved in support of this theory and evidence exists to suggest 
that in some models and under appropriate conditions, immunosurveillance can play 
an active role in suppressing the growth of early tumors. Hence in this paradigm, 
when tumors do successfully grow, they are thought to have escaped from 
surveillance and a number of reviews have been written to support this theory 
(56,78,97). 
The following will focus on the multiple mechanisms that exist leading to “tumor-
escape” from the immune system; these factors have to be taken into consideration 
when designing novel therapeutic strategies. The aim of this review is to highlight the 
required mechanisms of tumor escape and how they influence the failure of 
immunotherapy. 
 
Activation versus Suppression during Tumor Progression. 
Escape from immune-surveillance is a major mechanism for tumors to grow 
progressively.  Tumors may grow undetected by the immune system, being seen as 
“normal tissue” hence benefiting from any mechanism that makes them appear 
“healthy” and less dangerous i.e. exhibiting no danger signals for immune activation 
(56,86). It is believed that even during progressive growth the tumor has the ability to 
activate the immune system, and that a fine balance between activation and 
suppression exists, which determines the fate of the tumor. Tumor vaccines may 
induce activation and expansion of specific CD8+ T cells and destruction of tumor 
cells in cancer patients; this was observed in approximately 5-20% of vaccinated 
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melanoma patients. However, this activation can be fraught by the lack of appropriate 
co-stimulation or the presence of immunosuppressive cytokines such as IL-10 and 
TGF-β. The eventual fate of the tumor is therefore determined by the net effect of 
immune activation and inhibition. (56). 
Killing of tumor cells in situ by suicide gene transfer to induce cell death through a 
nonapoptotic pathway was shown to be associated with enhanced immunogeneicity 
(74). Similar observations were also reported by our group where immunisation with 
irradiated RENCA cells (murine renal carcinoma) infected with DISC-HSV (Disabled 
Infectious Single Cycle – Herpes Simplex Virus) that enhanced immunity to tumor 
challenge with live parental tumor cells that induced cell death by necrosis as opposed 
to apoptosis (5) providing the immune system with additional activation as the cells 
were undergoing necrotic cell lysis enhanced tumor antigen processing and 
presentation by APCs and hence an increase in T cell activation (59,70).  
 The mechanisms of tumor escape from immune recognition / destruction are likely to 
be multifactorial including downregulation of MHC Class I molecules (4,52,96,131), 
loss of tumor antigens (26,44), defective death receptor signalling (24,47,73,116,117), 
lack of co-stimulation (104), production of immunosuppressive cytokines (85) and 
suppressive cells (12,35,61,72,113) as shown in figure 1. 
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Figure 1:- A schematic diagram summarising the processes of activation and 
suppression during tumor progression. 
 
Involvement of Indoleamine 2,3 –dioxygenase in immunosuppression. 
 The mechanisms that mediate immune tolerance to cancer are not well understood, 
but recent findings have implicated the tryptophan/IDO (indoleamine 2,3-
dioxygenase) metabolic pathway as one of many mechanisms involved. IDO is an 
enzyme ubiquitously distributed in mammalian tissues and cells converting 
tryptophane to N-formylkynurenine (34). This cytosolic enzyme catalyses the initial 
and rate limiting step in the catabolism of tryptophan in the kynurenine pathway (76). 
Low levels of tryptophan at the tumor site causes T cells to arrest in the G1 phase of 
the cell cycle (125). Initially the enzyme was recognised for its anti-microbial activity 
by allowing cells to deplete tryptophan from intracellular pool or local 
microenvironment (114), however recently, IDO was reported to be constitutively 
expressed by most human tumors and its expression by immunogenic mouse tumor 
cells prevents their rejection in pre-immunised mice, correlating with the lack of 
specific T cell accumulation at the tumor site (125).  
IDO expression is an inducible feature of splenic DC subsets, and provides a potential 
explanation for their ability to regulate T cells. Induction of IDO completely blocked 
the clonal expansion of T cells from TCR transgenic mice following the 
administration of the immunomodulatory reagent CTLA4-Ig, whereas the same 
treatment did not block T cell clonal expansion in IDO-deficient recipients. 
Suppression of allogeneic T cell responses in vitro and in vivo by interstitial APC was 
also shown to be IDO-dependent and blockade of IDO activity with 1-MT (1-methyl-
cytokines and / or 
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DL-tryptophan (3)) or addition of exogenous tryptophan allowed the recovery of T 
cell proliferation in MLR assays (115). In humans, only a discrete subset of APCs that 
co-express the cell-surface markers CD123 and CCR6 was shown to express IDO and 
inhibit T cell proliferation in vitro (79). These results clearly demonstrated that the 
IDO pathway might represent a potential mechanism for DCs to regulate the immune 
response to tumor antigens. 
 
 Loss / Downregulation of HLA Class I. 
Altered MHC class I antigen expression in tumors is a well known phenomena. The 
selective loss of MHC class I alleles was subsequently described in a variety of mouse 
models including the TL leukaemic cell line, MCA-induced tumors and murine 
leukaemia virus induced tumors. The altered phenotypes of MHC Class I antigen 
expression permits tumor cells to avoid recognition or survive attack by CD8+ T-cells 
capable of mediating cytotoxicity. This phenomenon has been studied in a series of 
tumor samples by immunohistochemical techniques and has been shown to be 
widespread (58). 
HLA Class I molecule downregulation occurs frequently in many cancers and this 
abnormality might adversely affect the clinical course of disease and the outcome of T 
cell based immunotherapies. Over the past few years HLA Class I expression has 
been characterised in human tumors. Changes in HLA Class I expression can occur 
through various mechanisms – namely, mutations in genes and abnormalities in the 
regulation and/or defects in HLA Class I dependent antigen processing. These 
mutations modulate the susceptibility of tumor cells to in vitro lysis by CTLs and 
natural killer (NK) cells. Immune selection of tumor resistant CTLs and/or NK cells 
may explain the rapid progression and poor prognosis of cancers exhibiting HLA 
Class I antigen downregulation (43). 
To date a number of investigators have classified the types of HLA Class I loss into 
different phenotypes, and Table 1 summarises the HLA phenotypes that are 
recognised. 
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Table 1: Major HLA phenotypes in tumors and the associated molecular mechanisms. 
(Adapted from Cabrera et al 2003 (16)). 
 
HLA Phenotype Mechanisms References 
(I) HLA Class I Total Loss β2m mutations 
Alterations in antigen processing 
machinery 
37,55,88 
37,105 
(II) HLA haplotype Loss LOH in chromosome 6 31,37,91,92 
(III) HLA Allelic Loss Mutations of HLA Class I genes 13,37 
(IV) HLA A, B, C locus downregulation Alteration of transcriptional factors 37,39,110 
(V) Compound phenotype 2 or more independent mechanisms 37,45,93 
 
 
 A number of studies have been carried out to assess HLA Class I expression in 
tumors. In bladder carcinomas, 72% of the tumors studied showed at least one 
alteration in HLA expression and these were classified into different phenotypes 
depending on the type of downregulation/loss (18); expression was correlated to the 
degree of differentiation and tumor recurrence. To determine the type of HLA loss 
occurring during tumor progression, tissue samples from breast, colorectal and 
laryngeal carcinomas were analysed (17). HLA-B44 allele loss was observed more 
frequently than any other HLA Class I allele – suggesting an important role for this 
allele in tumor escape.  
Furthermore, mechanisms of MHC Class I loss were also investigated in colorectal 
carcinoma (15). It was shown that β2m mutation and LMP7 / TAP2 downregulation 
were responsible for the total loss of MHC class I expression-which contribute to the 
failure of T cell recognition during the immune response. 
In murine models, the B9 primary tumor clone (H-2 negative) and its metastatic 
colonies were studied in immunocompetent Balb/c mice (37). They showed that 83% 
of the metastasis obtained in different syngeneic Balb/c mice repeatedly exhibited a 
phenotype different from the original B9 clone. The alterations were identical in 
different colonies of different syngeneic Balb/c mice.  
Variation in the MHC Class I expression following immunotherapy has been 
observed in a murine colon carcinoma model (Ahmad, Ali, and Rees, unpublished 
observation). The CT26 (colon carcinoma) murine tumor model was used to 
investigate the expression of MHC Class I antigens in mice failing to regress their 
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tumors following immunotherapy (progressor) and tumor bearer (no therapy) animals 
(6). The DISC-HSV/mGM-CSF vector used in this study is an attractive tool for the 
delivery of cytokines to the tumors (11,94,120). This vector was developed by 
genetically inactivating the HSV-2 for use as a vaccine, by the deletion of the 
essential glycoprotein H (gH) gene – restricting it to one cycle of replication (11). On 
infection, the virus would release non-infectious particles together with the transduced 
cytokine e.g. GM-CSF. In our model the DISC therapy was administered 
intratumorally to mice with established subcutaneous (s.c) tumors, and approximately 
40% of the treated animals fail therapy and the tumors continue to grow progressively 
(3,6). MHC Class I (H-2Ld) expression was investigated in both tumor bearing and 
progressor mice. The results (Table 2) clearly demonstrated that a high proportion 
(55%) of tumors from progressor mice showed loss of class I MHC antigen, unlike 
the control tumors (treated with PBS) all of which expressed MHC I antigen. 
Interestingly, the tumor cells from the progressor animals re-expressed Class I 
following overnight in vitro culture, suggesting that the tumor micro-environment 
may be responsible for the transient downregulation of Class I expression as opposed 
to a mutation in the 2m gene  (95) or a downregulation in LMP7 / TAP 2 as reported 
in other studies (15). 
 
Table 2: A total of 18 tumors were studied (11 progressors, 7 PBS controls) for the 
expression of H2Ld. The results have been combined for the immunohistochemistry 
and FACS analysis, such that 45% of the therapy failures completely lost H2Ld 
surface expression whereas the tumor bearer animals retained a degree of expression 
(low, partial or full expression) (A.Talasila – MSc. Thesis, Nottingham Trent 
University, UK). 
 
 
 
 
Recently a number of studies have investigated the expression of Class II in patients. 
Antigen – presenting cells are crucial for the induction of an antigen – specific 
immune response and downregulation / loss of expression in cell surface molecules 
such as HLA Class II may contribute to an impaired immune response.  This 
phenomena was observed in PBMs of melanoma patients (123).  A number of 
Treatment No Expression 
(%) 
Low Expression 
(%) 
Partial Expression 
(%) 
Full Expression 
(%) 
Tumor Bearer 0 29 29 42 
DISC/mGM-CSF 45 28 27 0 
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different carcinomas (breast, ovarian and prostate) have been investigated for the 
expression of MHC Class I and II antigens (62, 69, 107) where the absence / 
downregulation of these recognition molecules correlated with the tumor’s ability to 
avoid immune surveillance and development of metastatic dissemination of the 
malignancy. 
 
Down-regulation, mutation or Loss of Tumor Antigens. 
  Alterations in tumor associated antigen (TAA) expression is one of the mechanisms 
by which tumor cells can escape CTL detection. Modifications in the TAA expression 
can range from down-modulation to complete loss, and loss of antigen expression can 
occur independently of the deregulation of HLA Class I expression. Tumor antigen 
expression is known to be heterogeneous, even within the same tumor (56); and a 
decrease in the expression of gp100 and MART-1 was associated with disease 
progression (26,44). In spite of the presence of TAA-specific CTL, immunogenic 
tumors can eventually grow and kill the host in animal models. Tumor escape in the 
murine mastocytoma P815 tumor was shown to be due to the emergence of stable 
antigen-loss variants (124). 
Antigenic drift, a mechanism used by viruses to escape immune recognition, has 
recently been described for tumors. Transgenic mice expressing TCR for a single 
antigenic epitope have been used extensively in establishing antigenic mutation(s) as 
a mechanism for viral escape of T cell recognition (22,98).  A transgenic mouse line 
expressing TCR specific for tumor antigen P1A35-43 presented by H-2Ld was also 
developed and used to study tumor escape mechanisms. The recurrence of tumors in 
mice that have responded favourably to transgenic T cell adoptive therapy was found 
to correlate with the presence of tumor variants with mutations within the PIA epitope 
(9). These mutations severely diminish T cell recognition of the tumor antigen by a 
variety of mechanisms, including modulation of MHC: peptide interaction and TCR 
binding to MHC: peptide complex. In another study, using a SCID mouse model and 
MART-1/Melan-A-sepcific CD8+ T cell clone against autologuos melanoma, it was 
found that the in vivo immuno-selection of antigen-loss variants was dependent on the 
presence of sub optimal levels of antigen expression (66); and loss of the 
immunodominant T cell-defined MART-1/Melan-A antigen and downregulation of 
the TAP-1 gene has been identified in a recurrent metastatic melanoma. Restoring the 
"antigen loss" in the variant tumor cell line by simultaneously providing both the 
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MART-1/Melan-A gene (by retroviral transfer) and the TAP-1 gene (by a bioballistic 
approach) resulted in tumor cell sensitivity to MART-1/Melan-A-specific cytotoxic T 
lymphocytes suggesting antigen loss and downregulation of the peptide-transporter 
protein TAP-1 expression (68). The emergence of tumor escape variants is more 
likely to result after effective immunotherapies. 
 
Alterations in cell death receptor signalling. 
The expression of Fas Ligand (FasL), a well-known cell death receptor ligand, on 
tumor cells has been implicated in their evasion of immune-surveillance 
(20,24,90,116,117). Apoptosis mediated via CD95 (Fas/Apo-1) is a key regulator for 
the biology of normal and malignant cells. However, Fas surface expression does not 
necessarily render cells susceptible to FasL-induced death signals, suggesting a role 
for inhibitors of the apoptosis-signalling pathway.  Phosphatidylinositol 3'-kinase (PI3 
K) and Akt (protein kinase B) mediate the survival signal and allow cells to escape 
from apoptosis in various human cancers. PI3 K inhibitors, such as LY294002 
inhibited cell proliferation and increase apoptosis in the human gastric carcinoma cell 
line by the down-regulation of Mcl-2 and phosphorylated Bad proteins, which are 
anti-apoptotic factors and belong to the Bcl-2 family (84). Acquisition of apoptosis 
resistance is a typical mechanism of chemotherapy failure in small-cell lung cancer, 
which was correlated, with the over-expression of Bcl-2 (32). 
Defects in receptors/signalling can facilitate tumor cell survival and proliferation. The 
Fas/FasL complex forms and engages caspase-8 which autoactivates itself and cleaves 
caspase-3, -6 and –7 (101). The caspase-8 inhibitor, cellular FLICE-inhibitory protein 
(cFLIP) is expressed in many tumors making them resistant to death receptor 
mediated apoptosis (47). FLICE/caspase-8-inhibitory protein (cFLIP) is a recently 
identified intracellular inhibitor of caspase-8 activation that potently inhibits death 
signalling mediated by all known death receptors, including Fas, TNF-receptor (TNF-
R), and TNF-related apoptosis-inducing ligand receptors (TRAIL-Rs), The increased 
expression of cFLIP in tumor cells is thought to contribute to immunoresistance to T 
cells in vivo (73) while the downregulation/loss of Fas expression resists apoptosis. In 
patients with B-cell chronic lymphocytic leukemia (B-CLL cells), an increase in cell-
surface CD95 expression on T cells was associated with reduced progression-free 
probability and poorer survival (40). In TRAIL-mediated apoptosis, the loss of 
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expression of all TRAIL receptors can occur by many mechanisms including the loss 
of caspase-8 by chromosomal loss or mutation (42). 
 
Cells expressing low levels of Fas (Faslow) in the B16F10 tumor model grew more 
slowly in comparison to the cells expressing high levels of Fas. Faslow-cells when 
injected showed enhanced tumor growth in mice depleted of neutrophils, suggesting 
that inactivation of neutrophils was an important mechanism by which tumors could 
escape destruction (66). The expression of FasL has also been studied in cervix 
adenocarcinomas, where FasL appears to play an important role in immune evasion, 
progression and metastases of the tumor (53). In contrast, the intracellular expression 
of FasL in breast cancer and normal tissue, as determined by immunohistochemistry, 
is unlikely to be an important marker for immune evasion (90). The expression of 
membrane bound FasL (mFasL) on colon cancer cells as a potential mechanism to 
inhibit host immune function by inducing apoptosis of host lymphocytes was 
investigated  (109). mFasL can be cleaved to release a soluble FasL (sFasL) to spread 
the apoptosis induction effect within the environment. These findings have suggested 
sFasL as a mechanism by which tumor cells can avoid immune attack. 
 
Immunosuppressive Cytokines. 
Tumor cells produce a number of cytokines and chemokines that can have a 
suppressive effect on immune cells. In non-small cell lung cancer patients, the mRNA 
expression of IL-4, IL-10, TGF-alpha, and TGF-beta1 was significantly higher than 
that of IL-2, IL-12, IL-18 and INF-gamma as determined in pleural effusion and 
tumor tissue (64). This predominant expression of type II (immunosuppressive) 
cytokines mirrors an immunosuppressive state in the immunological 
microenvironment. Vascular endothelial growth factor (VEGF) is secreted by many 
tumors (121), and in the past few years VEGF has been required as a contributory 
factor in tumor escape. VEGF is not only important for tumor vascularisation but is 
also a key factor produced by solid tumors to inhibit immune recognition (82), and 
prevent DC differentiation and maturation by suppressing the transcription factor NF-
κB in haemotopoietic stem cells (85). Blocking NF-κB activation in haemotopoietic 
cells by tumor-derived factors is thought to be a mechanism by which tumor cells can 
directly down-regulate the ability of the immune system to generate an antitumor 
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response (85). Elevated VEGF blood concentrations have been correlated with poor 
prognosis in human neoplasms (65), possibly as a result of its angiogenic properties 
and/or its ability to suppress DC maturation (46,65). VEGF was negatively related to 
DC infilteration in immunohistochemical studies on resected lung cancer samples (46) 
and activation status of DC and the concentration of VEGF in the peripheral blood 
have been shown to reflect the malignancy of NSCLC (30).  
Supernatants collected from tumor cells of AML patients were shown to inhibit T cell 
activation, Th1 cytokine production and to prevent activated T cells from entering the 
cell cycle (14), however, no TGF-β, IL-10 or VEGF were detected. The T cell 
immunosuppression induced by AML cells provides a mechanism by which leukemic 
clones could evade T cell mediated lysis by inhibiting the NF-κB, c-myc and pRb 
pathways (14). The production of soluble factors such as VEGF, IL-10, TNF and 
TGF-β is a proposed mechanism for tumor cells to avoid immune recognition, and the 
effects of these factors appear to be two-fold: to inhibit a) the effector function and b) 
the development of the immune cells by acting in the early stages of immunopoiesis 
(82). 
IL-10 is a cytokine often quoted as being suppressive and high levels of IL-10 have 
been reported in patients with melanoma (33) and pancreatic cancer (10,77). IL-10 
has the ability to exert its effects in many ways:- it inhibits antigen presentation, IL-12 
production and the induction of Th1 responses in vivo (25,106). 
High concentrations of TGF-β are also found in cancer patients (122) and are usually 
associated with “tumor-progression” (38) and poor responses to immunotherapy (27). 
The levels of TGF-β are higher in patients with disseminated melanoma when 
compared to those with localised disease (60). TGF-β has also been shown to induce 
the overproduction of IL-10 in tumors, leading to immunosuppression of antitumor 
responses. This suppression was reversed and Th1 responses reconstituted on the 
administration of anti-TGF-β antibodies in vivo (67). 
 
Alterations in the expression of signal transduction molecules 
Many different mechanisms may contribute to immune evasion. In pancreatic cancer, 
the loss of signal transducing CD3 zeta chain (CD3ξ ) of TILs has been attributed to 
immune escape together with the production of immunosuppressive cytokines and 
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local impairment of TILs (126); CD3 zeta loss in many cases has also been correlated 
with elevated levels of IL-10 and TGF-β. The loss of the CD3ξ  chain has been 
studied extensively and has been proposed as a mechanism by which tumors are able 
to escape. The zeta chain is present as a large intracytoplasmic homodimer in the TCR 
forming part of the TCR-CD3 complex. It functions as a single transducer upon 
antigen binding. (50). Hence any alterations in this chain could result in changes in 
the signalling pathway.   In pancreatic cancer, the loss of signal transducing CD3ξ  
chain of tumor infilterating lymphocytes (TILs) has also been attributed to immune 
escape together with the production of immunosuppressive cytokines and local 
inactivation of TILs (126). Alterations in the expression of CD3ξ  chain has also been 
correlated with elevated levels of IL-10 alone or in association with the 
downregulation of IFN-γ  (81). A general downregulation / decreased expression the 
CD3ξ  chain has been reported in tumors such as cervical and colorectal carcinomas 
(57,80,103). In cervical cancer the reduced expression of the zeta chain was 
associated with a reduction in cellular functions such as the production of TNF (57). 
In contrast, PBMCs from breast cancer and colorectal carcinomas patients do not 
show a decrease in TCR zeta expression yet the former exhibit an impairment in T 
cell function (81). 
 
Lack of co-stimulation 
Most tumors do not regress and continue to grow in spite of the presence of 
spontaneous or antigen (vaccine)-induced immune responses. The existence of 
systemic immune responses may not by itself be sufficient to cope with the complex 
nature of tumor-host interactions because of factors: insufficient co-stimulation to 
induce T-cell response may further contribute to the lack of effective immunity. There 
are a number of molecules that normally perform co-stimulatory functions by 
interacting with their counter ligand/receptor on T cells to provide the critical second 
signal for T-cell and/or APC activation including: CD80 (B7-1) / CD86 (B7-2) 
binding to CD28 and CTLA4 respectively; CD40L on activated CD4 helper cells 
binding to CD40 receptors on APCs; human CD58 and mouse CD48 (LFA-3) binding 
to CD2; and CD54 (ICAM-1) binding to LFA-1. Members of the TNFR super-family 
including CD27, CD30, 4-1BB and OX40 have also been shown to transmit a co-
stimulation signals to leukocytes (41,108). 
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It is a recognised phenomenon that T cells are rendered anergic due to the lack of co-
stimulatory molecule(s) expression by tumor cells (104). Tumor cells are able to 
induce antigen-specific tolerance or anergy on the basis of MHC-1-restricted antigen 
presentation without the expression of co-stimulatory ligand(s) (1). This 
unresponsiveness however can be reversed when tumor cells are genetically modified 
to express co-stimulation molecules. Chen et al (19) showed that the insertion of 
genes encoding B7.1 and /or B7.2 molecules into tumors generally increases their 
immunogenicity.  
Recently, fusagene vectors were developed to encode multiple gene products as 
fusion proteins from a single cistron to increase the immunogenenicity of target tumor 
cells (36). Analysis of over 100 individual clones derived from human and murine 
tumor cell lines demonstrated efficient expression and biological activity of each of 
the proteins. Tricistronic viral vectors co-expressing IL-12 and B7.1 have been used 
in the immunotherapy of cancer (128); the vectors generated could be used in 
immunotherapy for the treatment of multiple myeloma and other cancers as they were 
shown to stimulate allogeneic mixed lymphocyte proliferation and provoke increases 
in CTL responses and IFN-γ  release from normal donor lymphocytes exposed to the 
parental U266 cells. 
In addition, co-stimulation through molecules like 4-1BB was also found to be critical 
in the expansion and differentiation of CTLs. Systemic administration of an agonistic 
mAb against 4-1BB enhanced the CD8 T-cell response, leading to the eradication of 
established AG104A sarcomas and P815 mastocytomas in vivo (75).  However, 
resistance to this treatment modality by a number of poorly immunogenic tumors, 
including the TC-1 lung carcinoma and B16-F10 melanoma, was shown to be due to 
tumor antigen-specific CTLs “ignorance” rather than anergy or deletion; breaking 
CTL ignorance by peptide immunisation was necessary for the anti-4-1BB to function 
to enhance T-cell responses (129). Given the importance of co-stimulation in the 
regulation of immune responses against cancer, the manipulation of this pathway to 
increase immunity represents a promising therapeutic approach. Co-stimulation 
through OX40L for example would be advantageous, since its expression is primarily 
detected on recently stimulated antigen specific CD4+ T cells (127, our unpublished 
data), which is considered advantageous for generating CD8+ T-cell responses and 
anti-tumor immunity.   
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Immunosuppressive  cells 
There are at least 2 types of cells that when produced can impose a suppressive effect 
on the host’s immune system (CD4+/ CD25+ T cells and Gr1+/ CD11b+ myeloid 
cells), hence providing the tumor with the opportunity to escape immune recognition. 
Elucidating the mechanism(s) of T cell unresponsiveness in cancer is critical for the 
design and application of an effective cancer immunotherapy. Inhibition of a number 
of T lymphocyte functions in tumor-bearing hosts has been extensively investigated  
(63,89), and suppressor cells have been shown to play a role in the progression of 
cancer (29). CD4+ CD25+ T cells are known to be immunoregulatory and are 
important in immunological tolerance to self-antigens (72) and inhibition of T cell 
proliferation (119). They constitute approximately 5-10% of the CD4+ T cells in both 
humans and rodents and their removal induces autoimmune diseases in various 
locations in the body. Sutmuller and colleagues (113) demonstrated that the depletion 
of CD4+ CD25+ T cells followed by an injection of an antibody which blocks CTLA-4 
enhanced T-cell reactivity to a known tumor associated antigen. However, it is 
thought that the mere depletion or blocking of T regulatory cells is not sufficient to 
successfully treat established tumors (8).  
The existence of anergic and functionally suppressive CD4+CD25+T cells was 
demonstrated in patients with melanoma undergoing immunisation with known 
melanoma antigens. The degree of inhibition of T cell proliferation was proportional 
to CD4+CD25+T cells present; the addition of IL-2 reversed their hypo-responsiveness 
and abrogated their suppressive function (51). An increase in CD4+CD25+ regulatory 
T cells was shown to be correlated with immunosuppression and tumor progression in 
patients with gastrointestinal malignancies (102). Increased numbers of CD4+CD25+T 
cells secreting TGF- was detected in tumor infiltrates from patients with early and 
late-stage epithelial tumors (130). These observations provide clear evidence for the 
contribution of CD4+CD25+T cells to immune dysfunction in cancer patients. 
Immunotherapy aimed at decreasing the role of regulatory T-cells would be 
advantageous to successfully treating cancer. 
In addition, immune suppression in tumor bearing mice has been attributed to the 
presence of cells with an immature myeloid phenotype that express the granulocyte – 
monocyte markers Gr1+/CD11b+ (12), and accumulate in the spleens and lymph nodes 
(71) and blood of tumor bearing mice (Ahmad, Ali and Rees, unpublished data). They 
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are capable of inhibiting antibody production, CTL generation, T cell function and 
lymphocytic proliferation (61,71). Accumulation of Gr1+/CD11b+ cells and their 
ability to inhibit the T cell function has been reported in cancer patients (7). The Gr1+ 
cells are also able to decrease CD3ξ  molecule expression significantly (83), and 
inhibit MHC Class I dependent antigen-specific CD8+ T-cell (35).  
 
Conclusion 
This review has highlighted the main mechanisms by which the tumors are known to 
escape from immune recognition. Given the many different potential mechanisms that 
tumors can acquire to avoid or subvert adaptive immunity, future generation 
immunotherapeutic strategies will need to consider not only how to promote antigen 
driven T and B lymphocyte responses and their effective targeting to residual tumor, 
but also to understand how the mechanism(s) of tumor escape can be dealt with. 
Current research is exploring the application of combination therapy that utilises 
several treatment modalities, which may include sequential chemo-, radio- and 
immunotherapy protocols. 
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